Similar companies
Income Statement (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Gross Profit | -64,000 | 2.2% |
| Cost of Revenue | 64,000 | 2.2% |
| Operating expense | 8M | 21.3% |
| Net Income | -7.7M | 21.3% |
| EBITDA | -7.1M | 22.6% |
Balance Sheet (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Total Assets | 78M | 8.4% |
| Total Liabilities | 29M | 3.8% |
| Total Equity | 49M | 10.9% |
| Shares Outstanding | 60M | 0.1% |
Cash Flow (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Cash from operations | -7M | 17.9% |
| Cash from investing | 25M | 4611.6% |
| Cash from financing | 120,000 | 100% |
EPS
Financial Highlights for Aldeyra Therapeutics in Q3 '25
Gross Profit stood at -64,000, marking a -2.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 64,000, a 2.2% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 8M, showing a -21.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -7.7M, showing a 21.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -7.1M, showing a 22.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Aldeyra Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
